211 related articles for article (PubMed ID: 33766814)
21. Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial).
Mitsuhashi A; Kawasaki Y; Hori M; Fujiwara T; Hanaoka H; Shozu M
BMJ Open; 2020 Feb; 10(2):e035416. PubMed ID: 32114477
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007.
Miller KD; Althouse SK; Nabell L; Rugo H; Carey L; Kimmick G; Jones DR; Merino MJ; Steeg PS
Breast Cancer Res Treat; 2014 Nov; 148(1):99-106. PubMed ID: 25257727
[TBL] [Abstract][Full Text] [Related]
23. 5-aza-2'-deoxycytidine improves the sensitivity of endometrial cancer cells to progesterone therapy.
Hu Q; Yu L; Chen R; Wang YL; Ji L; Zhang Y; Xie Y; Liao QP
Int J Gynecol Cancer; 2012 Jul; 22(6):951-9. PubMed ID: 22683940
[TBL] [Abstract][Full Text] [Related]
24. Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?
Yamagami W; Susumu N; Makabe T; Sakai K; Nomura H; Kataoka F; Hirasawa A; Banno K; Aoki D
J Gynecol Oncol; 2018 Mar; 29(2):e21. PubMed ID: 29400014
[TBL] [Abstract][Full Text] [Related]
25. Significance of p27 as a predicting marker for medroxyprogesterone acetate therapy against endometrial endometrioid adenocarcinoma.
Watanabe J; Watanabe K; Jobo T; Kamata Y; Kawaguchi M; Imai M; Okayasu I; Kuramoto H
Int J Gynecol Cancer; 2006; 16 Suppl 1():452-7. PubMed ID: 16515645
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcomes of fertility-sparing treatment of atypical polypoid adenomyoma with medroxyprogesterone acetate.
Nomura H; Sugiyama Y; Tanigawa T; Matoda M; Kanao H; Kondo E; Takeshima N
Arch Gynecol Obstet; 2016 Jan; 293(1):177-181. PubMed ID: 26209972
[TBL] [Abstract][Full Text] [Related]
27. Endometrial carcinoma remaining after term pregnancy following conservative treatment with medroxyprogesterone acetate.
Mitsushita J; Toki T; Kato K; Fujii S; Konishi I
Gynecol Oncol; 2000 Oct; 79(1):129-32. PubMed ID: 11006045
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger.
Ota T; Yoshida M; Kimura M; Kinoshita K
Int J Gynecol Cancer; 2005; 15(4):657-62. PubMed ID: 16014120
[TBL] [Abstract][Full Text] [Related]
29. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens.
Ørbo A; Arnes M; Vereide AB; Straume B
BJOG; 2016 Aug; 123(9):1512-9. PubMed ID: 26630538
[TBL] [Abstract][Full Text] [Related]
30. Reproductive epidemiology of glial tumors may reveal novel treatments: high-dose progestins or progesterone antagonists as endocrino-immune modifiers against glioma.
Altinoz MA; Ozpinar A; Elmaci I
Neurosurg Rev; 2019 Jun; 42(2):351-369. PubMed ID: 29453736
[TBL] [Abstract][Full Text] [Related]
31. [Hormonal therapy and chemotherapy of endometrial cancer].
Krauss T; Huschmand H; Hinney B; Viereck V; Emons G
Zentralbl Gynakol; 2002 Jan; 124(1):45-50. PubMed ID: 11873314
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer.
Tamauchi S; Kajiyama H; Utsumi F; Suzuki S; Niimi K; Sakata J; Mizuno M; Shibata K; Kikkawa F
J Obstet Gynaecol Res; 2018 Jan; 44(1):151-156. PubMed ID: 29121428
[TBL] [Abstract][Full Text] [Related]
33. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours.
Pili R; Salumbides B; Zhao M; Altiok S; Qian D; Zwiebel J; Carducci MA; Rudek MA
Br J Cancer; 2012 Jan; 106(1):77-84. PubMed ID: 22134508
[TBL] [Abstract][Full Text] [Related]
34. [Two cases of multidrug-resistant recurrent endometrial cancer successfully treated with medroxyprogesterone acetate (MPA)].
Nishio S; Koyanagi T; Miyabe K; Kuromatsu H
Gan To Kagaku Ryoho; 2010 Apr; 37(4):735-8. PubMed ID: 20414038
[TBL] [Abstract][Full Text] [Related]
35. Effect of high-dose progestogen on hemostatic properties of blood in patients with endometrial cancer.
Kaibara M; Watanabe T; Ooka F; Liang SG; Aisaka K; Okinaga S
Clin Hemorheol Microcirc; 2001; 24(2):93-9. PubMed ID: 11381184
[TBL] [Abstract][Full Text] [Related]
36. Cyclic and sequential therapy with tamoxifen and medroxyprogesterone acetate in metastatic breast cancer.
Nemoto T; Patel JK; Rosner D; Dao TL; Halvorson H
J Surg Oncol; 1989 Aug; 41(4):226-9. PubMed ID: 2526907
[TBL] [Abstract][Full Text] [Related]
37. Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome.
Lu KH; Loose DS; Yates MS; Nogueras-Gonzalez GM; Munsell MF; Chen LM; Lynch H; Cornelison T; Boyd-Rogers S; Rubin M; Daniels MS; Conrad P; Milbourne A; Gershenson DM; Broaddus RR
Cancer Prev Res (Phila); 2013 Aug; 6(8):774-81. PubMed ID: 23639481
[TBL] [Abstract][Full Text] [Related]
38. Medroxyprogesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus-usefulness and limitations.
Imai M; Jobo T; Sato R; Kawaguchi M; Kuramoto H
Eur J Gynaecol Oncol; 2001; 22(3):217-20. PubMed ID: 11501776
[TBL] [Abstract][Full Text] [Related]
39. Endometrial carcinoma in a young patient with polycystic ovarian syndrome: first suspected at time of embryo transfer.
Salha O; Martin-Hirsch P; Lane G; Sharma V
Hum Reprod; 1997 May; 12(5):959-62. PubMed ID: 9194647
[TBL] [Abstract][Full Text] [Related]
40. Failure of down-regulation of estrogen receptors and progesterone receptors after medroxyprogesterone acetate administration for endometrial hyperplasias.
Masuzawa H; Badokhon NH; Nakayama K; Konishi I; Nikaido T; Fujii S
Cancer; 1994 Oct; 74(8):2321-8. PubMed ID: 7922983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
